Matches in Nanopublications for { ?s ?p "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP215206.RA8TnmsdV3RNrtQQVQKOBIEJBn2j3HDB4XxxuEylMSZTA130_assertion description "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215206.RA8TnmsdV3RNrtQQVQKOBIEJBn2j3HDB4XxxuEylMSZTA130_provenance.
- NP586804.RAsX1ZNeLWx-2M9FG4qhHxTplJQqnerIpci7jdJLdcbSo130_assertion description "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586804.RAsX1ZNeLWx-2M9FG4qhHxTplJQqnerIpci7jdJLdcbSo130_provenance.
- NP713740.RA0W1SFnu3tzECL9iabH4aCVJFIBdxbzZ6kyFcCfX53D0130_assertion description "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP713740.RA0W1SFnu3tzECL9iabH4aCVJFIBdxbzZ6kyFcCfX53D0130_provenance.
- assertion description "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP714833.RAlNSfgnenUNiwsRLqhElWC3XSEiSujZoxOtI-2SRfXnQ130_assertion description "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP714833.RAlNSfgnenUNiwsRLqhElWC3XSEiSujZoxOtI-2SRfXnQ130_provenance.
- NP555703.RA8kglzVPbB88S_XwTW0gHC_CnMzhUZ4dkmuVo60ZuIsY130_assertion description "[As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP555703.RA8kglzVPbB88S_XwTW0gHC_CnMzhUZ4dkmuVo60ZuIsY130_provenance.